Thank you for sharing!

Your article was successfully shared with the contacts you provided.

WAYNE, NJ-Bayer Healthcare has decided to base its US operations at existing company facilities here and in Montville. The decision is part of a reorganization of the company’s operations in the wake of its acquisition, in June, of Schering AG Germany and the subsequent integration with Schering’s US affiliate, Berlex.

The real estate specifics haven’t been announced, but the headquarters consolidation is expected to focus on existing Berlex sites at 6 West Belt Rd. here, and 340 Changebridge Rd. in Montville.

The reorganization plan calls for the closure of Bayer’s existing US locations in West Haven, CT and Richmond, CA, with as many as 350 jobs moving to New Jersey from those locations, and possibly from another location in the Seattle area. The larger reorganization is expected to eliminate 600 jobs in the short term and another 200 later.

“The changes will leverage the combined assets of Schering and Bayer to maximize both the output and effectiveness of our drug discovery and development programs. They also give us the flexibility to substantially lower our ongoing infrastructure costs,” says Arthur Higgins, board chairman of Bayer Healthcare and of Bayer Schering Pharma AG.

“We can now bring together a critical mass of functions into a cohesive US headquarters units,” says Gunnar Riemann, a member of the board of Bayer Schering Pharma.

The move to New Jersey comes with substantial state aid. The New Jersey EDA has approved a Business Employment Incentive Program (BEIP) grant involving a rebate of nearly two-thirds of the amount of state income taxes that Bayer’s transferred staffers will pay. Based on the 350 employees expected to be transferred, the grant is estimated to be worth $12.5 million over the next decade. Prior to the latest grant, Berlex had previously received nearly $5 million in state aid relating to moving and retaining jobs at its two New Jersey locations.

The larger reorganization involves a total of a half-dozen Schering or Bayer locations across the country. According to a statement released by Bayer officials, one-time costs of $350 million will be incurred, of which about $200 million are non-cash. The company expects to cut its overall R&D costs by more than $210 million, and the reorganization is expected to be completed over the next 12 to 18 months.

Bayer’s perhaps better-known consumer products division already has a major presence in the Garden State. The maker of Bayer Aspirin, Alka-Seltzer and Aleve, among other products, has its US headquarters in Morristown.

Want to continue reading?
Become a Free ALM Digital Reader.

Once you are an ALM digital member, you’ll receive:

  • Unlimited access to GlobeSt and other free ALM publications
  • Access to 15 years of GlobeSt archives
  • Your choice of GlobeSt digital newsletters and over 70 others from popular sister publications
  • 1 free article* every 30 days across the ALM subscription network
  • Exclusive discounts on ALM events and publications

*May exclude premium content
Already have an account?



Join GlobeSt

Don't miss crucial news and insights you need to make informed commercial real estate decisions. Join GlobeSt.com now!

  • Free unlimited access to GlobeSt.com's trusted and independent team of experts who provide commercial real estate owners, investors, developers, brokers and finance professionals with comprehensive coverage, analysis and best practices necessary to innovate and build business.
  • Exclusive discounts on ALM and GlobeSt events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com.

Already have an account? Sign In Now
Join GlobeSt
Live Chat

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.